Evidence map›Paper›PMID 27780490›Full record

ArticleEpidemiology and infection2017

Evaluation of the limiting antigen avidity EIA (LAg) in people who inject drugs in Greece.

G K Nikolopoulos, A Katsoulidou, M Kantzanou, C Rokka, C Tsiara, V Sypsa, D Paraskevis, M Psichogiou, S Friedman, A Hatzakis

Open access · bronzeAbstract readEvaluation Study
In one paragraph

Article in Epidemiology and infection, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Molecular investigation of HIV-1 cross-group transmissions during an outbreak among people who inject drugs (2011-2014) in Athens, Greece.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2018
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

G K NikolopoulosMedical School, University of Cyprus, Nicosia, Cyprus.
A KatsoulidouDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, University of Athens, Athens, Greece.
M KantzanouDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, University of Athens, Athens, Greece.
C RokkaDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, University of Athens, Athens, Greece.
C TsiaraHellenic Centre for Disease Control and Prevention, Amarousio, Greece.
V SypsaDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, University of Athens, Athens, Greece.
D ParaskevisDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, University of Athens, Athens, Greece.
M PsichogiouFirst Department of Internal Medicine, Laiko General Hospital, University of Athens, Athens, Greece.
S FriedmanNational Development and Research Institutes (NDRI), New York, USA.
A HatzakisDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, University of Athens, Athens, Greece.
National and Kapodistrian University of Athens · GRHellenic Center for Disease Control & Prevention · GRNational Development and Research Institutes · US

Funding

Transdisciplinary Theoretical Svnthesis and Development CoreP30DA011041 · NIDA · NEW YORK UNIVERSITY · PI Holly Hagan · 1998 to 2026
$38.9M
Preventing HIV Transmission by Recently-Infected Drug UsersDP1DA034989 · NIDA · NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES, INC. · PI FRIEDMAN, SAMUEL R · 2012 to 2016
$3.8M
NIDA NIH HHS DP1 DA034989NIDA NIH HHS P30 DA011041
6 · The paper itself

Abstract

This analysis assessed the utility of the limiting antigen avidity assay (LAg). Samples of people who inject drugs (PWID) in Greece with documented duration of HIV-1 infection were tested by LAg. A LAg-normalized optical density (ODn) ⩽1·5 corresponds to a recency window period of 130 days. The proportion true recent (PTR) and proportion false recent (PFR) were estimated in 28 seroconverters and in 366 samples collected >6 months after HIV diagnosis, respectively. The association between LAg ODn and HIV RNA level was evaluated in 232 persons. The PTR was 85·7%. The PFR was 20·8% but fell to 5·9% in samples from treatment-naive individuals with long-standing infection (>1 year), and to 0 in samples with the circulating recombinant form CRF35 AD. A LAg-based algorithm with a PFR of 3·3% estimated a similar incidence trend to that calculated by analyses based on HIV-1 seroconversions. In recently infected persons indicated by LAg, the median log10 HIV RNA level was high (5·30, interquartile range 4·56-5·90). LAg can help identify highly infectious HIV(+) individuals as it accurately identifies recent infections and is correlated with the HIV RNA level. It can also produce reliable estimates of HIV-1 incidence.

Indexed as

Antibody AffinityDiagnostic ErrorsAdultFemaleGreeceHIV AntibodiesHIV InfectionsHumansImmunoenzyme TechniquesMaleRNA, ViralSubstance Abuse, IntravenousViral LoadHIV AntibodiesRNA, ViralDrug injectorsHIVincidenceLAgrecent infection

Identifiers

PMID27780490
PMCPMC6824880
OpenAlexW2542152626

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.